Publication: Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): First report and review of literature
Issued Date
1997-12-17
Resource Type
ISSN
03922936
Other identifier(s)
2-s2.0-9844255061
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Gynaecological Oncology. Vol.18, No.6 (1997), 453-456
Suggested Citation
Surintip Piamsomboon, Andrzej P. Kudelka, Wichai Termrungruanglert, Koen Van Besien, Creyhton L. Edwards, Samuel Lifshitz, Donald F. Schomer, Richard Champlin, Rosario P. Mante, John J. Kavanagh, Claire F. Verschraegen Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): First report and review of literature. European Journal of Gynaecological Oncology. Vol.18, No.6 (1997), 453-456. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/18010
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): First report and review of literature
Abstract
Gestational trophoblastic disease (GTD) metastatic to the brain has a very poor prognosis with a survival rate of less than 25%, especially for patients in whom brain metastases develop while on or after chemotherapy. Cure can be achieved by chemotherapy alone. The regimen of etoposide, methotrexate, actinomycin-D, vincristine, and cyclophosphamide has shown encouraging results and is considered to be standard first-line treatment for high risk patients. For patients in whom this regimen fails, a salvage chemotherapy regimen is used. The combination of ifosfamide, carboplatin, and etoposide (ICE) has synergistic activity in preclinical studies. This regimen has shown activity in metastatic breast cancer and non-small-cell lung cancer as well as platinum-resistant germ-cell tumors and metastatic GTD. This is the first report of a patient with a highly refractory GTD in whom brain metastasis developed while on chemotherapy, and whose brain metastasis went into remission with a low dose ICE regimen. Accordingly, ICE may be considered for patients with chemotherapy refractory GTD metastatic to the brain.